Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Heparin sodium + allantoin is a topical combination therapy primarily utilized in dermatology for the treatment of scars and inflammatory skin conditions. Heparin sodium, a biological glycosaminoglycan, exerts anti-inflammatory, anti-proliferative, and anti-edematous effects when applied topically; it also promotes the hydration of collagen tissue and improves local microcirculation. Allantoin acts as a skin-conditioning agent that stimulates epithelialization, promotes wound healing, and possesses keratolytic and soothing properties. While traditionally indicated for hypertrophic and keloidal scars, recent clinical research, including studies by The Second Affiliated Hospital of Xi'an Jiaotong University, has explored its efficacy in treating rosacea by targeting inflammatory erythema and improving skin barrier function. In many regions, this combination is marketed as a 'compound' gel that may also include onion extract (Ext. Cepae).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on heparin sodium + allantoin.